- Home
- BIVI vs NERV Comparison
BIVI vs NERV Comparison
Compare BIVI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- NERV
- Stock Information
- Founded
- BIVI 2013
- NERV 2007
- Country
- BIVI United States
- NERV United States
- Employees
- BIVI N/A
- NERV N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- BIVI Health Care
- NERV Health Care
- Exchange
- BIVI Nasdaq
- NERV Nasdaq
- Market Cap
- BIVI 11.9M
- NERV 12.0M
- IPO Year
- BIVI N/A
- NERV 2014
- Fundamental
- Price
- BIVI $1.82
- NERV $2.22
- Analyst Decision
- BIVI
- NERV Hold
- Analyst Count
- BIVI 0
- NERV 1
- Target Price
- BIVI N/A
- NERV $5.00
- AVG Volume (30 Days)
- BIVI 323.5K
- NERV 21.0K
- Earning Date
- BIVI 11-12-2025
- NERV 11-04-2025
- Dividend Yield
- BIVI N/A
- NERV N/A
- EPS Growth
- BIVI N/A
- NERV N/A
- EPS
- BIVI N/A
- NERV 1.48
- Revenue
- BIVI N/A
- NERV N/A
- Revenue This Year
- BIVI N/A
- NERV N/A
- Revenue Next Year
- BIVI N/A
- NERV N/A
- P/E Ratio
- BIVI N/A
- NERV $1.47
- Revenue Growth
- BIVI N/A
- NERV N/A
- 52 Week Low
- BIVI $1.42
- NERV $1.15
- 52 Week High
- BIVI $75.00
- NERV $3.00
- Technical
- Relative Strength Index (RSI)
- BIVI 33.82
- NERV 46.30
- Support Level
- BIVI $1.54
- NERV $2.06
- Resistance Level
- BIVI $2.03
- NERV $2.25
- Average True Range (ATR)
- BIVI 0.15
- NERV 0.11
- MACD
- BIVI 0.23
- NERV -0.03
- Stochastic Oscillator
- BIVI 65.57
- NERV 12.55
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.